دورية أكاديمية
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma
| العنوان: | Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma |
|---|---|
| المؤلفون: | Goldlust, Samuel A, Nabors, Louis B, Hsu, Sigmund, Mohile, Nimish, Duic, Paul J, Benkers, Tara, Singer, Samuel, Rao, Mayank, Cappello, Lori, Silberman, Sandra L, Farmer, George |
| المساهمون: | Cortice Biosciences |
| المصدر: | Neuro-Oncology Advances ; volume 6, issue 1 ; ISSN 2632-2498 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Surgery, Oncology, Neurology (clinical) |
| الوصف: | Background Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab (BEV) for the treatment of rGBM. Methods GBM patients with up to 2 prior relapses without prior exposure to anti-angiogenic therapy were eligible. A standard 3 + 3 design was utilized to determine the maximum tolerated dose (MTD) of TPI 287. Cohorts received TPI 287 at 140–220 mg/m2 every 3 weeks and BEV 10 mg/kg every 2 weeks during 6-week cycles. An MRI was performed after each cycle, and treatment continued until progression as determined via response assessment in neuro-oncology criteria. Results Twenty-four patients were enrolled at 6 centers. Treatment was generally well tolerated. Fatigue, myelosuppression, and peripheral neuropathy were the most common treatment emergent adverse events. Dose-limiting toxicity was not observed, thus the MTD was not determined. Twenty-three patients were evaluable for median and 6-month progression-free survival, which were 5.5 months (mo) and 40%, respectively. Median and 12-month overall survival were 13.4 mo and 64%, respectively. The optimal phase 2 dose was determined to be 200 mg/m2. Conclusions TPI 287 can be safely combined with BEV for the treatment of rGBM and preliminary efficacy supports further investigation of this combination. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/noajnl/vdae009 |
| DOI: | 10.1093/noajnl/vdae009/56253259/vdae009.pdf |
| الإتاحة: | https://doi.org/10.1093/noajnl/vdae009Test https://academic.oup.com/noa/article-pdf/6/1/vdae009/56618340/vdae009.pdfTest |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.6E38D95A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/noajnl/vdae009 |
|---|